Literature DB >> 6375329

Disparate unloading efficacy of the calcium channel blockers, verapamil and nifedipine, on the failing hypertensive left ventricle.

M D Guazzi, C Cipolla, P Della Bella, F Fabbiocchi, P Montorsi, P Sganzerla.   

Abstract

Calcium channel blockers reduce arterial smooth muscle tone and lower blood pressure. They may be regarded as left ventricular (LV) unloading agents. LV unloading efficacy of nifedipine (15 patients) and verapamil (14 patients) was tested in hypertensive decompensated patients, during a 1-month treatment period. Nifedipine persistently reduced systemic vascular resistance (SVR), mean arterial pressure, mean pulmonary wedge pressure (PWP), and LV diastolic diameter, and improved cardiac index and velocity of circumferential fiber shortening (Vcf). All of the patients had relief from dyspnea and reduction in heart size. The only side effect was ankle edema in six. Verapamil reduced SVR and mean arterial pressure and was not effective on PWP, LV diastolic diameter, and Vcf. The drug was discontinued in two patients who developed severe dyspnea at rest after 3 to 4 days of continuous oral treatment. Clinical symptoms and signs did not improve in the remaining patients despite persistent pressure reduction. A less potent vasodilating action of verapamil and a prominent depression in cardiac contractility may account for the differential results with the two compounds, in spite of a shared vasodilating antihypertensive effect. These findings indicate that functional changes in the failing hypertensive heart may differ from one calcium blocker to another as a result of interaction and relative preponderance of influence on afterload and contractility.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6375329     DOI: 10.1016/0002-8703(84)90553-2

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  7 in total

Review 1.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 2.  Calcium antagonists in patients with heart failure. A review.

Authors:  H Reicher-Reiss; E Barasch
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 3.  Calcium antagonists and chronic cardiac failure.

Authors:  M J Kendall; R C Horton; S R Smith
Journal:  Postgrad Med J       Date:  1986-08       Impact factor: 2.401

Review 4.  Hypertension.

Authors:  Suzanne Oparil; Maria Czarina Acelajado; George L Bakris; Dan R Berlowitz; Renata Cífková; Anna F Dominiczak; Guido Grassi; Jens Jordan; Neil R Poulter; Anthony Rodgers; Paul K Whelton
Journal:  Nat Rev Dis Primers       Date:  2018-03-22       Impact factor: 52.329

5.  Afterload reduction: a comparison of captopril and nifedipine in dilated cardiomyopathy.

Authors:  P G Agostoni; N De Cesare; E Doria; A Polese; G Tamborini; M D Guazzi
Journal:  Br Heart J       Date:  1986-04

Review 6.  Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

Review 7.  The haemodynamic effects of nifedipine, verapamil and diltiazem in patients with coronary artery disease. A review.

Authors:  A L Soward; G L Vanhaleweyk; P W Serruys
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.